Compounds > vaticanol b

Page last updated: 2024-11-12

vaticanol b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vaticanol B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10010985
CHEMBL ID	2368899
MeSH ID	M0512752

Synonyms (3)

Synonym
vaticanol b
CHEMBL2368899
(1r,2s,3s,9r,10r,17r)-3-[(2r,3r)-3-(3,5-dihydroxyphenyl)-6-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzofuran-4-yl]-2,9,17-tris(4-hydroxyphenyl)-8-oxapentacyclo[8.7.2.04,18.07,19.011,16]nonadeca-4(18),5,7(19),11(16),12,14-hexaene-5,13,15-triol

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	30.0000	0.0004	1.8773	10.0000	AID641150
Sucrase-isomaltase, intestinal	Rattus norvegicus (Norway rat)	IC50 (µMol)	294.0000	0.0400	1.8483	10.0000	AID641148
Lysosomal alpha-glucosidase	Rattus norvegicus (Norway rat)	IC50 (µMol)	233.0000	0.0800	2.5061	9.8500	AID641146
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID1171264	Inhibition of YopE in Yersinia pseudotuberculosis YPIII PIB102-Elux measured after 3 hrs 15 mins by luminescent reporter-gene assay	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Solving the supply of resveratrol tetramers from Papua New Guinean rainforest anisoptera species that inhibit bacterial type III secretion systems.
AID641150	Inhibition of rat lens aldose reductase using DL-glyceraldehyde as substrate after 30 mins by fluorescence microplate reader analysis	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1171265	Inhibition of YopH in Yersinia pseudotuberculosis YPIII PIB102-Elux using p-nitrophenyl phosphate as substrate measured after 3 hrs 15 mins by phosphatase enzyme assay	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Solving the supply of resveratrol tetramers from Papua New Guinean rainforest anisoptera species that inhibit bacterial type III secretion systems.
AID641146	Inhibition of alpha-glucosidase activity of maltase in rat small intestinal brush border membrane fraction using maltose as substrate after 30 mins	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID504234	Cytotoxicity against human foreskin fibroblast at 1 uM	2010	Journal of natural products, Sep-24, Volume: 73, Issue:9	Resveratrol oligomers from Vatica albiramis.
AID641148	Inhibition of alpha-glucosidase activity of sucrase in rat small intestinal brush border membrane fraction using maltose as substrate after 30 mins	2012	Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2	Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID504233	Antiinflammatory activity in human foreskin fibroblast assessed as inhibition of IL-1-beta-induced MMP1 production at 1 uM treated for 24 hrs before IL1-beta challenge measured after 24 hrs by Western blot analysis	2010	Journal of natural products, Sep-24, Volume: 73, Issue:9	Resveratrol oligomers from Vatica albiramis.
AID1171267	Antimicrobial activity against Yersinia pseudotuberculosis YPIII PIB102-Elux at 364 uM by spectrophotometry	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Solving the supply of resveratrol tetramers from Papua New Guinean rainforest anisoptera species that inhibit bacterial type III secretion systems.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.72 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.66 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
phlorhizin [no description available]	2.07	1	0	aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative	antioxidant; plant metabolite
streptomycin [no description available]	2.1	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.46	2	0
acarbose [no description available]	2.07	1	0	amino cyclitol; glycoside
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.49	2	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.03	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	2.1	1	0	stilbene
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.07	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.03	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
polydatin trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.	2.07	1	0	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator
epsilon-viniferin epsilon-viniferin: stilbene dimer; isolated from the Oriental medicinal plant Vitis coignetiae; structure given in first source. (-)-trans-epsilon-viniferin : A stilbenoid that is the (-)-trans-stereoisomer of epsilon-viniferin, obtained by cyclodimerisation of trans-resveratrol.	2.05	1	0	1-benzofurans; polyphenol; stilbenoid	metabolite
malibatol a malibatol A: an oligostilbene from leaves of Hopea malibato; structure in first source	2.07	1	0
vaticanol c vaticanol C: structure in first source	2.47	2	0
hopeaphenol hopeaphenol: resveratrol tetramer in wines from North Africa	2.1	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Chronic Hepatitis C [description not available]	0	2.6	1	0
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	2.6	1	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	0	7.6	1	0
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	0	2.6	1	0
Innate Inflammatory Response [description not available]	0	2.03	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.03	1	0